*** ADVOCACY ALERT ***
NORD Calls Bill Passed By Senate Today Most Important Since Orphan Drug Act
Praises Senate for Addressing Needs of Rare Disease Patients
May 22, 2012, WASHINGTON, DC— The National Organization for Rare Disorders (NORD) applauds legislation passed today by the U.S. Senate — S 3187, the Food and Drug Administration Safety & Innovation Act of 2012 (FDASIA) — and says it contains the most comprehensive improvements to public policy for rare disease therapies since the landmark Orphan Drug Act of 1983. [Read more...]

